NASDAQ:IPA ImmunoPrecise Antibodies (IPA) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free IPA Stock Alerts $1.52 -0.05 (-3.18%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$1.50▼$1.6450-Day Range$1.40▼$2.4152-Week Range$0.94▼$4.22Volume320,153 shsAverage Volume1.66 million shsMarket Capitalization$40.01 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get ImmunoPrecise Antibodies alerts: Email Address ImmunoPrecise Antibodies MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside360.5% Upside$7.00 Price TargetShort InterestHealthy2.04% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.74Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.36) to ($0.26) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.22 out of 5 starsMedical Sector651st out of 938 stocksPharmaceutical Preparations Industry305th out of 435 stocks 3.5 Analyst's Opinion Consensus RatingImmunoPrecise Antibodies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.00, ImmunoPrecise Antibodies has a forecasted upside of 360.5% from its current price of $1.52.Amount of Analyst CoverageImmunoPrecise Antibodies has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.04% of the float of ImmunoPrecise Antibodies has been sold short.Short Interest Ratio / Days to CoverImmunoPrecise Antibodies has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ImmunoPrecise Antibodies has recently increased by 1,290.22%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldImmunoPrecise Antibodies does not currently pay a dividend.Dividend GrowthImmunoPrecise Antibodies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IPA. Previous Next 3.7 News and Social Media Coverage News SentimentImmunoPrecise Antibodies has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for ImmunoPrecise Antibodies this week, compared to 0 articles on an average week.Search Interest12 people have searched for IPA on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.MarketBeat Follows8 people have added ImmunoPrecise Antibodies to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ImmunoPrecise Antibodies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.83% of the stock of ImmunoPrecise Antibodies is held by insiders.Percentage Held by InstitutionsOnly 6.70% of the stock of ImmunoPrecise Antibodies is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ImmunoPrecise Antibodies are expected to grow in the coming year, from ($0.36) to ($0.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ImmunoPrecise Antibodies is -3.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ImmunoPrecise Antibodies is -3.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunoPrecise Antibodies has a P/B Ratio of 1.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About ImmunoPrecise Antibodies Stock (NASDAQ:IPA)ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.Read More IPA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IPA Stock News HeadlinesMarch 28, 2024 | finance.yahoo.comInterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare ApplicationsMarch 28, 2024 | businesswire.comInterSystems and IPA's Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare ApplicationsMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 28, 2024 | americanbankingnews.comShort Interest in ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Rises By 1,290.2%March 20, 2024 | businesswire.comIPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI DevelopmentsMarch 19, 2024 | americanbankingnews.comImmunoPrecise Antibodies (NASDAQ:IPA) Stock Rating Reaffirmed by BenchmarkMarch 19, 2024 | americanbankingnews.comImmunoPrecise Antibodies (NASDAQ:IPA) Rating Reiterated by BenchmarkMarch 19, 2024 | americanbankingnews.comImmunoPrecise Antibodies (NASDAQ:IPA) Earns Speculative Buy Rating from BenchmarkMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 19, 2024 | americanbankingnews.comImmunoPrecise Antibodies (NASDAQ:IPA) Receives Speculative Buy Rating from BenchmarkMarch 19, 2024 | americanbankingnews.comHC Wainwright Reiterates Buy Rating for ImmunoPrecise Antibodies (NASDAQ:IPA)March 15, 2024 | msn.comImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q3 2024 Earnings Call TranscriptMarch 14, 2024 | investorplace.comIPA Stock Earnings: ImmunoPrecise Antibodies Misses EPS, Beats Revenue for Q3 2024March 7, 2024 | finance.yahoo.comIPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT TechnologyMarch 7, 2024 | businesswire.comIPA's subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT TechnologyMarch 4, 2024 | finance.yahoo.comIPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024 on March 14, 2024December 16, 2023 | markets.businessinsider.comBuy Rating on ImmunoPrecise Antibodies Reflects Strong Revenue Growth and Cost Management SuccessDecember 8, 2023 | finance.yahoo.comIPA Announces Closing of $1.265 Million Public Offering of Common SharesDecember 6, 2023 | benzinga.comWhy ImmunoPrecise Antibodies (IPA) Stock Is Down 20% TodayDecember 6, 2023 | investorplace.comWhy Is ImmunoPrecise Antibodies (IPA) Stock Down 39% Today?December 6, 2023 | finance.yahoo.comIPA Announces Pricing of $1.1 Million Public Offering of Common SharesDecember 5, 2023 | investing.comAfter-hours movers: SentinelOne up on earnings, MongoDB sees 'sell the news' reactionDecember 5, 2023 | finance.yahoo.comIPA Announces Proposed Public Offering of Common SharesNovember 27, 2023 | businesswire.comImmunoPrecise Antibodies Ltd. Announces Key Board and Board Committee Chair Appointments and Second Quarter 2024 Earnings Release CallNovember 22, 2023 | finance.yahoo.comImmunoPrecise’s BioStrand(R) Unifies Diverse Data Modalities, Launches AI-Driven Platform For Enhanced Drug DiscoveryNovember 20, 2023 | benzinga.comImmunoPrecise's BioStrand® Unifies Diverse Data Modalities, Launches AI-Driven Platform For Enhanced Drug DiscoveryOctober 25, 2023 | stockhouse.comIPA's Subsidiary, BioStrand, Provides an Update on LENSai(TM)See More Headlines Receive IPA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmunoPrecise Antibodies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/29/2024Fiscal Year End4/30/2024Next Earnings (Estimated)7/08/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:IPA CUSIPN/A CIK1715925 Webwww.immunoprecise.com Phone250-483-0308FaxN/AEmployees102Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$9.00 Low Stock Price Target$5.00 Potential Upside/Downside+360.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,980,000.00 Net Margins-60.23% Pretax Margin-66.12% Return on Equity-26.54% Return on Assets-18.36% Debt Debt-to-Equity Ratio0.25 Current Ratio1.66 Quick Ratio1.38 Sales & Book Value Annual Sales$15.61 million Price / Sales2.56 Cash FlowN/A Price / Cash FlowN/A Book Value$1.40 per share Price / Book1.09Miscellaneous Outstanding Shares26,320,000Free Float24,518,000Market Cap$40.01 million OptionableNot Optionable Beta0.12 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Jennifer Lynne Bath Ph.D.CEO, President & Non-Independent DirectorDr. Ilse RoodinkChief Scientific Officer & Interim General Manager of IPA Europe, OssMs. Kristin Taylor CPAM.B.A., Chief Financial OfficerMr. David E. OrtonChief Operating OfficerDr. Roland RomijnHead of General Operations of the Utrecht site of IPA (Europe)Key CompetitorsCara TherapeuticsNASDAQ:CARAVYNE TherapeuticsNASDAQ:VYNEBriaCell TherapeuticsNASDAQ:BCTXMarker TherapeuticsNASDAQ:MRKRDURECTNASDAQ:DRRXView All CompetitorsInstitutional OwnershipCitadel Advisors LLCSold 4,900 shares on 2/15/2024Ownership: 0.000%Northern Trust CorpBought 60,914 shares on 2/13/2024Ownership: 0.231%Simplex Trading LLCBought 100 shares on 2/2/2024Ownership: 0.000%Ingalls & Snyder LLCBought 253,052 shares on 1/29/2024Ownership: 4.868%View All Institutional Transactions IPA Stock Analysis - Frequently Asked Questions Should I buy or sell ImmunoPrecise Antibodies stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ImmunoPrecise Antibodies in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IPA shares. View IPA analyst ratings or view top-rated stocks. What is ImmunoPrecise Antibodies' stock price target for 2024? 2 equities research analysts have issued 12 month price targets for ImmunoPrecise Antibodies' shares. Their IPA share price targets range from $5.00 to $9.00. On average, they expect the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 360.5% from the stock's current price. View analysts price targets for IPA or view top-rated stocks among Wall Street analysts. How have IPA shares performed in 2024? ImmunoPrecise Antibodies' stock was trading at $1.71 at the beginning of 2024. Since then, IPA stock has decreased by 11.1% and is now trading at $1.52. View the best growth stocks for 2024 here. Are investors shorting ImmunoPrecise Antibodies? ImmunoPrecise Antibodies saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 440,700 shares, an increase of 1,290.2% from the February 29th total of 31,700 shares. Based on an average trading volume of 571,700 shares, the days-to-cover ratio is currently 0.8 days. Currently, 2.0% of the company's shares are short sold. View ImmunoPrecise Antibodies' Short Interest. When is ImmunoPrecise Antibodies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, July 8th 2024. View our IPA earnings forecast. Who are ImmunoPrecise Antibodies' major shareholders? ImmunoPrecise Antibodies' stock is owned by many different retail and institutional investors. Top institutional shareholders include Ingalls & Snyder LLC (4.87%), Northern Trust Corp (0.23%), Citadel Advisors LLC (0.00%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of ImmunoPrecise Antibodies? Shares of IPA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IPA) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyMost important medical advance in 100 yearsThe Oxford ClubBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunoPrecise Antibodies Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.